Kyverna Therapeutics, Inc.
Have updates for this profile? Please contribute data
= Subscriber Access Only
You are viewing a preview of this profile. Request a Preqin Pro demo for full access to all profiles and underlying data.
With Preqin Pro, you gain an unobstructed view of all alternative asset class activity across institutional investors, fund managers, funds, portfolio companies, deals, exits, and service providers.
Kyverna Therapeutics, Inc. - overview
Established
2018
Location
Emeryville, CA, US
Primary Industry
Biotechnology
About
Founded in 2018 by founder Jeffrey Greve, and based in California, US, Kyverna Therapeutics, Inc. is a biotechnology company that operates a cell therapy platform. In October 2025, Kyverna Therapeutics, Inc. raised USD 150 million in venture debt funding from investor Oxford Finance.
The facility includes an initial tranche of USD 40 million and two additional tranches totaling USD 60 million, subject to the satisfaction of certain terms and conditions of the loan and security agreement. A fourth tranche of USD 50 million may also be made available subject to Oxford Finance’s discretion. As of November 2025, the company is led by CEO Warner Biddle. Kyverna Therapeutics researches and develops cell therapies for patients with autoimmune diseases.
As of 2024, the company’s product portfolio includes KYV-101, a CAR (chimeric antigen receptor) T-cell therapy undergoing clinical trials to treat diseases such as multiple sclerosis, myasthenia gravis, systemic sclerosis, and lupus nephritis. The treatment functions by resetting the immune system and targeting B cell-driven haematological malignancies to treat rheumatology and neurology-based autoimmune diseases.
Current Investors
Gilead Sciences, Inc., Vida Ventures, Westlake Village BioPartners
Primary Industry
Biotechnology
Sub Industries
Molecular Science, Genetics & Gene Therapy, Healthcare Specialists
Website
www.kyvernatx.com
Verticals
HealthTech
Company Stage
Series B
Total Amount Raised
Subscriber access only
Kyverna Therapeutics, Inc. - deals
| Deals Type | Deal Status | Target (s) | Deal Date | Investor(s) | Seller(s) | Deal size (Mn) | Enterprise value (Mn) | Post-money valuation (Mn) | EBITDA multiple (x) | Revenue multiple (x) | Lead partner (s) |
|---|---|---|---|---|---|---|---|---|---|---|---|
| IPO | Completed | Kyverna Therapeutics, Inc. | - |
Displaying 1 - 1 of 1
Time to go Pro
Get Preqin Pro for unrestricted access to 600,000+ detailed profiles on fund managers, investors, funds, companies, and other alternative asset players. Unlock exclusive data on future plans, company financials, fundraising history, track records, and more.